BERLIN, May 10 (Reuters) – BioNTech announced on Monday plans to create a regional headquarters and build a new production plant for its messenger RNA (mRNA) vaccines in Singapore as the latest step to expand its production network.
The Mainz-based company has announced plans to open Singapore in 2021 and expects the production site to be operational until 2023, creating up to 80 jobs in Singapore.
“Having nodes in our production network is a vital strategic step in building our global presence and capabilities,” said Ugur Sahin, CEO and co-founder of BioNTech.
(Reporting through Caroline Copley)